U.S. markets closed

Synlogic, Inc. (SYBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4000+0.2400 (+7.59%)
At close: 4:00PM EDT

Synlogic, Inc.

301 Binney Street
Suite 402
Cambridge, MA 02142
United States
617 401 9975

Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMScPres, CEO & Director737.3kN/A1976
Dr. Richard J. Riese M.D., Ph.D.Chief Medical Officer209.16kN/A1963
Dr. Timothy K. LuCo-FounderN/AN/AN/A
Dr. James J. CollinsCo-FounderN/AN/A1967
Mr. Gregg D. BeloffInterim Chief Financial OfficerN/AN/A1968
Mr. Antoine AwadChief Operating OfficerN/AN/AN/A
Dr. David L. HavaChief Scientific OfficerN/AN/A1975
Dr. Elizabeth WolffeHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Daniel RosanSr. VP, Head of Fin. & Investor RelationsN/AN/AN/A
Mr. Adam ThomasChief People Officer & Sec.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Corporate Governance

Synlogic, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.